强化移植排斥免疫抗肿瘤作用的实验研究

 抑制移植排斥免疫是为了使移植器官能够在受者体内长期存活，而本文试图用强化移植排斥免疫的方法来达到抗肿瘤的目的。结果表明：在实验1中用人k562细胞强化免疫的小鼠，其存活期为45.4±17.6天，显著长于对照组的22.0±10.1天和BCG组的25.0±14.0天，在实验2中用人Raji细胞或异种肿瘤RA759肺癌细胞、大鼠脾细胞加BCG强化免疫的昆明系小鼠，在十天后接种H22肝癌细胞，其存活期分别为：40.0±7.6天，41.9±5.4天，39.3±7.5天及45.0天，均显著长于对照组的25.3±6.6天（P＜0.04），尤以大鼠脾细胞加BCG强化免疫的昆明系小鼠预防肿瘤的效果为好，在45天内无1只死亡，且有5/10的小鼠出现肿瘤消退或局限的现象。在接种H22肝癌细胞后第45天处死荷瘤鼠，取肝、脾及胸腺称重，各组间肝、脾及胸腺重量无统计学差别（P＞0.05）。提示强化移植排斥免疫不影响荷瘤鼠的主要免疫器官。

Antitumor Effects of Enhanced Rejection Immune with Xenogeneic Spleen Cells or Tumor Cells on Mice

Generally, in order to prevent rejection of grafts, immune inhibitors such as CsA are used to suppress lymphocytes function of recipients. But in this report we transplanted xenogeneic spleen cills or tumor cells with BCG on mice, by means of this to suppress tumor growth of recipient mice. The results showed that the survial time of the tumor bearing mice with ERI were significantly longer than of control group and suggest that the ERI might be used as a new metod of immunotherapy to treat and prevent cancer.